Agents and preparation methods for blocking abnormal angiogenesis using enhanced lead editing
By editing dual non-integrated lentiviral agents that produce stop codon mutations at VEGFR2 gene loci, the problem of drug resistance in the treatment of angiogenesis diseases in the prior art is solved, effective inhibition of retinal angiogenesis is achieved, and PDR is provided new treatment options for blinding diseases.
Patent Information
- Application Number
- CN202311711932.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-12-13
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2043-12-13
AI Technical Summary
Prior Art In the treatment of angiogenesis-related diseases, many patients develop resistance to existing antagonists, resulting in poor treatment effects, especially in blinding diseases such as PDR, where effective new treatment methods are lacking.
Develop an agent that blocks abnormal angiogenesis by carrying LTR-U6-epegRNA-EF1α-nSpCas9-RT-LTR and LTR-U6-nicking sgRNA-EF1α-MLH1dn-LTR targeting genome VEGFR2 Dual non-integrated lentiviruses, editing the VEGFR2 gene loci, produce stop codon mutations to block VEGFR2 expression and activity, thereby inhibiting abnormal retinal angiogenesis.
This agent provides a potential new therapeutic strategy by significantly improving the efficiency of VEGFR2 gene editing, producing DN-VEGFR2, effectively blocking retinal angiogenesis, showing the potential for preventing pathological retinal angiogenesis in OIR mouse models. Go beyond the limitations of traditional anti-VEGF drugs.
Smart Images

Figure CN117717632B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of ophthalmic disease prevention and treatment, and more specifically, to a drug and a preparation method for blocking abnormal angiogenesis by enhanced lead editing. Background Art
[0002] Angiogenesis is the process by which new blood vessels sprout from pre-existing ones and is associated with a variety of human diseases, including tumor growth, cancer metastasis, proliferative diabetic retinopathy (PDR), retinopathy of prematurity (ROP), and neovascular age-related macular degeneration (nAMD).
[0003] The vascular endothelial growth factor (VEGF) / VEGF receptor (VEGFR) 2 signaling pathway is essential for angiogenesis (Holmes et al., 2007), and therefore many antagonists, such as ranibizumab, bevacizumab, aficicept, sorafenib, and sunitinib, which block this pathway, have been developed to treat angiogenesis-related human diseases. Despite this, countless patients still develop resistance to these therapies. Therefore, new therapeutic approaches are urgently needed to treat angiogenesis-related diseases, including PDR, which accounts for the largest proportion of acquired blindness in the working-age population. Summary of the invention
[0004] The technical problem to be solved by the present invention is that, in view of the above-mentioned defects of the prior art, a drug for blocking abnormal angiogenesis by enhanced lead editing is provided, and an inhibitory drug for blocking abnormal angiogenesis by enhanced lead editing is also provided.
[0005] The technical solution adopted by the present invention to solve its technical problem is:
[0006] An agent for blocking abnormal angiogenesis using enhanced prime editing is constructed, wherein the agent carries LTR-U6-epegRNA-EF1α-nSpCas9-RT-LTR and LTR-U6-nicking sgRNA-EF1α-MLH1dn-LTR targeting genomic VEGFR2.
[0007] The agent for blocking abnormal angiogenesis using enhanced lead editing of the present invention, wherein the agent is prepared by transfecting an integrase-deficient packaging vector carrying the mutation D64V, a vector expressing a lentiviral envelope, and a plasmid of LTR-U6-epegRNA-EF1α-nSpCas9-RT-LTR or LTR-U6-nicking sgRNA-EF1α-MLH1dn-LTR into 293T cells to prepare an integrase-deficient lentivirus to carry LTR-U6-epegRNA-EF1α-nSpCas9-RT-LTR or LTR-U6-nicking sgRNA-EF1α-MLH1dn-LTR.
[0008] The agent for blocking abnormal angiogenesis using enhanced lead editing described in the present invention, wherein the LTR-U6-epegRNA-EF1α-nSpCas9-RT-LTR is used to express the SpCas9n fusion protein of the structured RNA sequence epegRNA driven by the U6 promoter and the codon-optimized RT driven by the EF1α core promoter.
[0009] The agent for blocking abnormal angiogenesis by enhanced lead editing of the present invention, wherein the LTR-U6-nicking sgRNA-EF1α-MLH1dn-LTR is used to express the nicking sgRNA and dominant negative MLH1.
[0010] A method for preparing a drug that blocks abnormal angiogenesis using enhanced lead editing, wherein the method is as follows:
[0011] Construct LTR-U6-epegRNA-EF1α-nSpCas9-RT-LTR carrying U6-epgRNA and SpCas9n fusion protein sequence;
[0012] LTR-U6-nicking sgRNA-EF1α-MLH1dn-LTR carrying U6-sgRNA and EF-1α-MLHdn was constructed.
[0013] The method for preparing a drug for blocking abnormal angiogenesis using enhanced lead editing of the present invention, wherein the drug is prepared by transfecting an integrase-deficient packaging vector carrying the mutation D64V, a vector expressing a lentiviral envelope, and a plasmid of LTR-U6-epegRNA-EF1α-nSpCas9-RT-LTR or LTR-U6-nicking sgRNA-EF1α-MLH1dn-LTR into 293T cells to prepare an integrase-deficient lentivirus to carry LTR-U6-epegRNA-EF1α-nSpCas9-RT-LTR or LTR-U6-nicking sgRNA-EF1α-MLH1dn-LTR.
[0014] The method for preparing a drug for blocking abnormal angiogenesis using enhanced lead editing of the present invention, wherein the LTR-U6-epegRNA-EF1α-nSpCas9-RT-LTR is derived from lent-crispr v2 by replacing SpCas9 with SpCas9n-ert and then inserting a synthetic epegRNA.
[0015] The method for preparing a drug for blocking abnormal angiogenesis using enhanced lead editing of the present invention, wherein the pLTR-U6-sgRNA-EF-1-MLH1dn-LTR is derived by replacing SpCas9 with MLH1dn using lenti-crispr v2, and then the ngRNA is inserted through BsmB1.
[0016] The method for preparing a drug for blocking abnormal angiogenesis using enhanced lead editing of the present invention, wherein the ngRNA is prepared by the method of: annealing the top oligonucleotide 5'CACCG-TCATCCAAGGGCAATTCATC and the bottom oligonucleotide 5'-aaac-20nt-c-3', 20nt being a complementary top oligonucleotide sequence.
[0017] The method for preparing a drug for blocking abnormal angiogenesis by enhanced lead editing according to the present invention further comprises the steps of:
[0018] LTR-U6-epegRNA-EF1α-nSpCas9-RT-LTR or LTR-U6-nicking sgRNA-EF1α-MLH1dn-LTR, lentiviral envelope plasmid VSV-G and lentiviral packaging plasmid psPAX2 or integrase-deficient lentiviral packaging transfection mixture;
[0019] The transfection mixture was incubated at room temperature, transferred to a cell culture dish, and the lentivirus was collected by centrifuging the virus-containing medium and suspending the virus particles in sterile TNE buffer.
[0020] The beneficial effect of the present invention is that the agent of the present application edits the VEGFR2 gene site through LTR-U6-epegRNA-EF1α-nSpCas9-RT-LTR and LTR-U6-nicking sgRNA-EF1α-MLH1dn-LTR, so that the earlier mutation of retinal VEGFR2 T17967A produces a stop codon (TAG, K796stop) and DN-VEGFR2, thereby blocking the expression and activity of retinal VEGFR2, blocking abnormal retinal angiogenesis in the OIR mouse model, and achieving the purpose of preventing pathological retinal angiogenesis. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the present invention will be further described below in conjunction with the accompanying drawings and embodiments. The drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work:
[0022] Figure 1A is a schematic diagram of the dual integrase-deficient lentivirus for delivering PE6;
[0023] Figure 1B is a schematic diagram of generating mutant VEGFR2 (K796stop) using PE6;
[0024] Figure 1C is a schematic diagram of complete and dominant negative VEGFR2;
[0025] Figure 2A is a schematic diagram of Western blot analysis of clarified lysates of mouse vascular endothelial cells (MVECs);
[0026] Figure 2B is a schematic diagram of the quantification of protein blot band intensity;
[0027] Figure 3A is a schematic diagram of Sanger DNA sequencing analysis;
[0028] Figure 3B is a schematic diagram of the next-generation sequencing (NGS) analysis of PCR products of MVECs genomic loci;
[0029] Figure 3C is a schematic diagram of Western blot analysis of transduced MVECs lysates using the indicated antibodies;
[0030] Figure 4A is a schematic diagram of Western blot analysis of mouse endothelial cell lysate;
[0031] Figure 4B It is a schematic diagram of western blot band intensity data of three representative experiments;
[0032] Figure 5A It is to establish an OIR model;
[0033] Figure 5B The stained whole retina was photographed under a fluorescence microscope;
[0034] Fig. 6A It is staining analysis;
[0035] Figure 6B It is the VEGFR2 T17967A (K796stop) mutation that occurs in the mouse retina;
[0036] Figure 6C was Western blot analysis of retinal lysates;
[0037] Fig. 7A is the hematoxylin and eosin staining of retinal sections after intravitreal injection of NILV-PE6 targeting VEGFR2 or lacZ;
[0038] Figure 7B Electroretinography is used to diagnose retinal function. DETAILED DESCRIPTION
[0039] In order to make the purpose, technical solutions and advantages of the embodiments of the present invention clearer, the following will be described clearly and completely in combination with the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are partial embodiments of the present invention, not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work belong to the protection scope of the present invention.
[0040] A preferred embodiment of the present invention is a drug for blocking abnormal angiogenesis using enhanced lead editing, wherein the drug carries LTR-U6-epegRNA-EF1α-nSpCas9-RT-LTR (LV5) and LTR-U6-nickingsgRNA-EF1α-MLH1dn-LTR (LV6) targeting genomic VEGFR2;
[0041] The agent of the present application edits the VEGFR2 gene site through LTR-U6-epegRNA-EF1α-nSpCas9-RT-LTR and LTR-U6-nickingsgRNA-EF1α-MLH1dn-LTR, so that the earlier mutation of retinal VEGFR2 T17967A produces a stop codon (TAG, K796stop) and DN-VEGFR2, thereby blocking the expression and activity of retinal VEGFR2, blocking abnormal retinal angiogenesis in the OIR mouse model, and achieving the purpose of preventing pathological retinal angiogenesis.
[0042] Retroviruses that deliver DN-VEGFR2 directly to animal models have been shown to inhibit tumor angiogenesis (Machein et al., 1999; Stratmann et al., 2001) and wound angiogenesis (Tsou et al., 2002). These previous studies laid the foundation for the use of dual non-integrating lentiviruses NILVs to deliver PE6 (LTR-U6-epegRNA-EF1α-nSpCas9-RT-LTR and LTR-U6-nicking sgRNA-EF1α-MLH1dn-LTR), which can edit the genomic VEGFR2 locus to produce endogenous DN VEGFR2, thereby inhibiting retinal angiogenesis; compared with retroviruses, NILVs have obvious advantages in safety due to their non-integrating behavior and higher infection efficiency.
[0043] Because NILVs are located in the eye, ocular immune privilege limits their potential immune response (Niederkorn, 2019; Taylor, 2009; Zhou and Caspi, 2010). Similarly, when anti-VEGF antibodies were first used to treat cancer patients, serious side effects were seen because VEGF is required for normal physiological activities (al-Husein et al., 2012; Chu et al., 2007; Kamba and McDonald, 2007; van Heeckeren et al., 2007), and these drugs (including ranibizumab and aflibercept) are the current standard of care for many blinding eye diseases such as neovascular age-related degeneration [nAMD] and PDR (Broadhead et al., 2022; Ehlers et al., 2022; Gragoudas et al., 2004). Therefore, DN-VEGFR2 generated using PE6 is expected to be a new strategy for treating intraocular angiogenesis, including PDR.
[0044] After PE came out in 2019 (Anzalone et al., 2019), we transfected the PE2 system targeting genomic VEGFR2 into 293T cells, but the results showed that only 0.5% editing was achieved (data not given in the article). This low editing efficiency may be due to ineffective pegRNA or MMR effect. When PE5 appeared in 2021 (Chen et al., 2021), we designed pegRNA using a web tool (Chow et al., 2021) and then added a structured RNA motif tevopreQ1 to its 3' end as an epegRNA to prevent its degradation (Nelson et al., 2022); in addition, we also used nicked RNA to nick the unedited chain (Anzalone et al., 2019) and used DN protein to inhibit MMR (Chen et al., 2021). Surprisingly, these optimized methods significantly improved the PE efficiency to more than 50% ( Figure 2A-2B However, based on these results, we attempted to further improve the editing efficiency by modifying the length of the PBS, but these efforts did not lead to additional improvements (data not shown in the article). Therefore, this dual vector system has broad application value for PE6.
[0045] Previous studies have used other gene editing strategies, including AAV-mediated and endothelial-specific promoter-driven SpCas9 targeting retinal VEGFR2 (Huang et al., 2017a), lentiviral delivery of SpCas9 mRNA targeting VEGF-A in retinal pigment epithelial cells, and AAV-mediated expression of Campylobacter jejuni Cas9 targeting VEGF-A (Kim et al., 2017), which reportedly inhibited intraocular angiogenesis in mouse models. Compared with these previous studies, primary editing has the advantage of increased safety due to its unbroken DNA double strands; compared with current intraocular anti-VEGF drugs, DN-VEGFR2 generated by primary editing has the dual functions of neutralizing VEGF and inhibiting VEGFR2 autophosphorylation, and may have a higher efficiency in inhibiting angiogenesis. In addition, although anti-VEGF drugs (such as ranibizumab and aflibercept) can inhibit angiogenesis and vascular leakage associated with ocular diseases (such as PDR and wet AMD), treatment still faces challenges.
[0046] In this study, we used an advanced prime editing (PE) system to generate a vascular endothelial growth factor receptor 2 (VEGFR2) T17967A mutation, thereby generating an earlier stop codon (TAG, K796stop) to generate DN-VEGFR2. The PE6 system targeting VEGFR2 led to the VEGFR2 T17967A mutation (51.1%), generated DN-VEGFR2, and inhibited VEGFR2-induced VEGFR2 phosphorylation by dual non-integrating lentiviruses (NILVs) transfected mouse vascular endothelial cells in vitro.
[0047] We then demonstrated in a mouse model of oxygen-induced retinopathy that retinal DN-VEGFR2 produced by intravitreal injection of dual NILVs could block retinal VEGFR2 expression and activation, as well as abnormal retinal angiogenesis, suggesting that DN-VEGFR2 produced by editing genomic VEGFR2 using the PE6 system could be used to treat pathological angiogenesis.
[0048] Combined with the attached drawings and experimental data, the following is explained: Description of the drawings:
[0050] Figure 1A-Figure 1C Schematic diagram of generating dominant negative VEGFR2 by priming editing;
[0051] Figure 1A .Schematic diagram of dual integrase-deficient lentivirus for delivery of PE6;
[0052] 1) Construct a lentiviral vector (LV5) carrying the U6-epgRNA and SpCas9n(H840A) fusion protein sequence driven by RT (enhanced codon-optimized reverse transcriptase) driven by the EF (elongation factor)-1α promoter. U6: U6 promoter, LTR: long terminal repeat.
[0053] ②Construct a lentiviral vector (LV6) carrying U6-sgRNA for nicking (ngRNA) and EF-1α-MLHdn. MLH1dn: MLH1 dominant negative.
[0054] The integrase-deficient packaging vector carrying mutation D64V (catalog#:63586, Addgene), the vector expressing the lentiviral envelope (catalog#:8454, Addgene), and the plasmid of LV5 or LV6 were transfected into 293T cells to prepare integrase-deficient lentivirus (LV5 or LV6). VSV-G: vesicular stomatitis virus-G protein.
[0055] Figure 1B. Schematic diagram of generating mutant VEGFR2 (K796stop) using PE6;
[0056] 1) Schematic diagram of the mouse VEGFR2 locus (NC_00071.6), showing the mutation at amino acid position 796, lysine (K).
[0057] 2) Schematic diagram of using PE6 to create VEGFR2 T17967A (K796stop);
[0058] RT template (16 nucleotides: nt): reverse transcription template, PBS (14 nt): primer binding sequence, PAM: protospacer adjacent motif, protospacer sequence used to generate sgRNA, PBS: primer binding site.
[0059] 3) PE6 was used to generate the epegRNA sequence of VEGFR2 T17967A (K796stop). tevopreQ1: truncated evopreQ1 sequence to protect epegRNA from degradation.
[0060] Figure 1C . Schematic diagram of complete and dominant negative VEGFR2;
[0061] Full VEGFR2 (1345aa): an extracellular domain combined with seven IgG domains connected by SS bonds, a plasma membrane domain for spanning the plasma membrane, and an intracellular domain combined with the kinase domain; dominant negative (DN) VEGFR2 (795aa) with an intracellular nephramine mutation (K796stop).
[0062] Figure 2A-2B , in mouse vascular endothelial cells, expression of NILV-delivered Cas9n-RT is transient;
[0063] Figure 2A Western blot analysis of clarified lysates from mouse vascular endothelial cells (MVECs) infected with non-integrating lentivirus (NILV:N) or lentivirus (LV:L) carrying a SpCas9n fusion protein (Cas9n) with enhanced reverse transcriptase (RT).
[0064] Figure 2B . Quantification of Western blot band intensity. Data are from three representative independent experiments. Ns: not significant, ****: p<0.0001 significant.
[0065] Figure 3A-3C , generating dominant negative VEGFR2 by in vitro priming editing;
[0066] Figure 3ASanger DNA sequencing analysis of PCR products from the genomic loci of MVECs transduced with double nilv carrying the PE6 system, including 1) SpCas9n fusion protein with enhanced reverse transcriptase (RT) and epegRNA targeting lacZ (as control) or VEGFR2, and 2) MLH1dn and nicking sgRNA targeting lacZ (as control) or VEGFR2. Genomic DNA transduced with pe6-targeting VEGFR2 contained a point mutation (PE6-VEGFR2), stop:stop codon (TAG).
[0067] Figure 3B .A. Next-generation sequencing (NGS) analysis of PCR products of MVECs genomic loci.
[0068] Figure 3C . Lysates of transduced MVECs were subjected to Western blot analysis using the indicated antibodies. Representative images are shown on the left and western blot band intensity data from three representative experiments are shown on the right (VEGFR2 vs. β-actin).
[0069] Figure 4A-4B , pe6-mediated dominant negative VEGFR2 can attenuate vegf-induced VEGFR2 activation in vitro;
[0070] Figure 4A Western blot analysis of lysates from mouse endothelial cells transduced with NILV-PE6 targeting VEGFR2 or lacZ (as a control) and stimulated with VEGF-A for 10 minutes after growth factor deprivation. A representative image is shown. L: lacZ, V: VEGFR2.
[0071] Figure 4B The bar graph shows the western blot band intensity data (p-VEGFR2 vs. β-actin) from 3 representative experiments.
[0072] Figure 5A-Figure 5B , NILVs transduce vascular endothelial cells in vivo;
[0073] Figure 5A NILVs expressing EGFP (1 μl, 5×109 IU / ml) were injected intravitreally into adult (A) or P12 mice (B) to establish the OIR model;
[0074] Figure 5B.5 days later, the mouse eyeballs were isolated and the whole-mount retina was stained with mouse endothelial cell marker IB4. The stained whole retina was photographed under a fluorescence microscope. Arrow: representative of GFP and IB4 fusion, scale bar: 200 μm.
[0075] Figure 6A-6C PE6-induced DN-VEGFR2 can inhibit pathological retinal angiogenesis in the oxygen-induced retinopathy mouse model;
[0076] Fig. 6A Representative IB4 staining analysis of retinal neovascularization in OIR P17 mice after intravitreal injection of NILV-PE6 targeting VEGFR2 or lacZ into P12 OIR mice (left). The bar graph is the ib4 staining data of the mouse retinas (n=6) injected intravitreally with NILV-PE6 targeting VEGFR2 or lacZ.
[0077] Figure 6B NGS analysis of mouse retinal genomic DNA The VEGFR2 T17967A (K796stop) mutation was generated in the retina of P17 OIR mice after intravitreal injection of NILV-PE6 targeting VEGFR2 or lacZ.
[0078] Figure 6C Retinal lysates were subjected to Western blot analysis using VEGFR2 N-terminal antibody. DN-VEGFR2 is the genotype.
[0079] Figure 7A-7B As shown, intravitreal injection of NILV-PE6 had no significant effect on retinal structure and function;
[0080] Fig. 7A .HE staining of retinal sections after intravitreal injection of NILV-PE6 targeting VEGFR2 or lacZ (n=4);
[0081] Figure 7B . After intravitreal injection of NILV-PE6 targeting VEGFR2 or lacZ, retinal function was diagnosed by electroretinography (n=9);
[0082] 1. Created a dual NILV system for delivering PE6;
[0083] Dual NILV System( Figure 1A), used for intravitreal delivery of PE6, resulting in the T17967A mutation in the mouse muscle VEGFR2 locus (NC_00071.6), which results in an earlier stop codon (TAG,K796stop) from AAG (K796) during VEGFR2 transcription and splicing in endothelial cells during pathogenic angiogenesis ( Figure 1B ).
[0084] We predicted that a dominant negative (DN) VEGFR2 with 795 amino acids (aa) would be generated during translation due to the stop codon (K796stop) generated by pe6 in the intracellular juxtamembrane domain ( Figure 1C ), and this DN VEGFR2 will block the VEGF / VEGFR2 signaling pathway, leading to the cessation of pathological retinal angiogenesis.
[0085] In the dual NILV system, LV5 was created to express epegRNA of a structured RNA sequence (TevopreQ1) driven by the U6 promoter and SpCas9n fusion protein (H840A) of a codon-optimized RT driven by the EF1α core promoter ( Anzalone et al., 2019 ; Sanjana et al., 2014 ), and LV6 will express excision sgRNA (ngRNA) and dominant negative MLH1 (MLHdn) ( Chen et al., 2021 ) Figure 1A-1B ).
[0086] To this end, we designed three vectors: 1) LV5 or LV6 containing epgRNA or ngRNA targeting genomic VEGFR2 (Sanjana et al., 2014), or the bacterial gene lacZ as a control; 2) an integrase-deficient packaging vector expressing Gag and Pol genes encoding RT and integrase with a D64V mutation that inactivates it (Certo et al., 2011); and 3) one expressing VSV (vesicular stomatitis virus)-G protein (Stewart et al., 2003), which were transfected together into human embryonic kidney (HEK) 293T cells to produce NILVs, and then NILV5 and NILV6 ( Figure 1A ) for concentration and titration for in vitro and in vivo use;
[0087] 2. PE6 produces dominant negative VEGFR2 in vitro;
[0088] To evaluate whether the dual NILV system was transiently expressed, we infected C57BL / 6 mouse primary brain microvascular endothelial cells (MVECs) (Huang et al., 2017a) with NILV5 or wild-type LV5 for different periods of time and performed Western blot analysis on their lysates. Figure 2A-2B As shown, the fusion protein with SpCas9n was expressed 6 hours after NILV5 infection, reached a peak at 48 hours, and was maintained until 72 hours after infection. It decreased by 51.2±2.6% at 96 hours, while SpCas9n / RT remained at almost the same level when infected with WT LV5, indicating that when the dual NILV system infected cells, SpCas9n / RT in PE6 was transiently expressed.
[0089] To explore whether PE6 can produce DN VEGFR2, we infected MVECs with a dual NILV system of NILV5 and NILV6 targeting genomic VEGFR2 or its control gene lacZ ( Figure 1A-Figure 1C ). On day 3 after infection, genomic DNA and proteins isolated from infected MVECs were analyzed by PCR and western blot, respectively. Sanger DNA sequencing of PCR products showed that the VEGFR2 locus had a T17967A mutation ( Figure 3A ), and next-generation sequencing (NGS) showed that T17967A reached 51.1% ( Figure 3B ).
[0090] This point mutation was designed to change AAG (K796) to TAG (stop codon), resulting in the dual NILV system producing DN VEGFR2 ( Figure 1A-Figure 1C As expected, western blot analysis showed that the expression of VEGFR2 fragments targeting VEGFR2 was reduced by 45.2±3.6% compared with that of VEGFR2 fragments targeting lacZ in MVECs infected with the dual NILV system ( Figure 3C ).
[0091] These results suggest that the T17967A mutation of PE6 in the genomic DNA of MVECs causes the translation of VEGFR2 mRNA to stop at an earlier stop codon, resulting in the generation of a new truncated protein: DN VEGFR2 (88 kDa), as well as decreased expression of WT VEGFR2.
[0092] 3. DN-VEGFR2 produced by PE6 blocked VEGFR2 activation induced by vegf;
[0093] DN proteins can inhibit the function of the corresponding WT proteins (Chen et al., 2021; I). Therefore, we next investigated whether DN-VEGFR2 produced by PE6 is sufficient to block the activity of WT VEGFR2, which is essential for angiogenesis (Huang et al., 2017a; Kiselev et al., 2007; Tsou et al., 2002). To answer this question, we treated mvecs infected with the dual NILV system on day 3 with or without VEGF (10 ng / ml) for 10 minutes and performed western blot analysis on their lysates. The results showed that DN VEGFR2 induced by PE6 reduced the level of VEGFR2 phosphorylation on Y951 by 79.8±3.5% ( Figure 4A-4B ).
[0094] 4. PE6-induced DN-VEGFR2 can inhibit pathological retinal angiogenesis in the oxygen-induced retinopathy mouse model;
[0095] Encouraged by the above in vitro experimental results, we next investigated whether DN-VEGFR2 could be generated in vivo by PE6 to inhibit retinal angiogenesis in the OIR mouse model. First, we evaluated whether NILV could infect retinal vascular endothelial cells in vivo by intravitreal injection of NILV carrying CMV-GFP (NILV-gfp) into 4-week-old mice or P12 mice undergoing the OIR model. Whole-mount retinas were obtained from mice on the 5th day after injection and stained with the mouse endothelial-specific marker isolectin 4 (IB4). The results showed that in the entire retina of NILV-GFP-injected mice, GFP signals co-localized with IB4 ( Figure 5A ), indicating that nilv can transduce retinal vascular endothelial cells. In addition, we also found that in the OIR mouse model, GFP is preferentially expressed in ECs of pathological blood vessels ( Figure 5B ),
[0096] We then injected equal amounts of NILV5 and NILV6 targeting mouse VEGFR2 or lacZ into the vitreous cavity of P12 mice in the OIR model. P7 mice were placed in a hyperoxic (75% oxygen) chamber for 5 days, during which central retinal blood vessel growth was inhibited; P12 mice were then returned to normal room air (21% oxygen). At this time, relative hypoxia induced normal central vascular regeneration and abnormal angiogenesis in the peripheral retina, called preretinal clusters. These clusters reached their maximum at P17. Therefore, whole-mount retinas of P17 mice injected with PE6 targeting VEGFR2 or lacZ were subjected to IB4 staining. As Fig. 6AAs shown, in mice injected with dual nilv targeting VEGFR2, the ib4-stained peripheral plexus was reduced by 93.5±2.1 and central retinal regeneration was reduced by 63.6±3.2% compared with mice targeting lacZ, indicating that DN VEGFR2 generated by PE6 in retinal vascular endothelial cells impedes hypoxia-induced retinal angiogenesis in the OIR mouse model.
[0097] To verify this speculation, genomic DNA and proteins extracted from the treated mouse retinas were subjected to next-generation sequencing (NGS) and western blot analysis, respectively. NGS results showed that about 11.8% of the retinal genomic DNA treated with double nilv targeting VEGFR2 had T17967A mutations, but no mutations targeting lacZ ( Figure 5B ); Western blotting analysis results showed that the VEGFR2 protein of mice injected with double nilv targeting VEGFR2 appeared smaller VEGFR2 compared with those mice targeting lacZ, and VEGFR2 was reduced by 22.6% ± 2.5 ( Figure 6C ). Taken together, these data indicate that PE6 can generate DN VEGFR2 from genomic VEGFR2 in vivo and that this DN VEGFR2 is sufficient to block hypoxia-induced angiogenesis in the OIR mouse model.
[0098] Notably, 4 weeks after dual intravitreal injection of nilv targeting genomic VEGFR2 into adult mice, no detectable damage to retinal morphology, structure, and function was found by hematoxylin-eosin histological staining and electroretinography (ERG) examination ( Figure 7A-7B ).
[0099] A method for preparing a drug that blocks abnormal angiogenesis by enhanced lead editing, wherein the method is as follows:
[0100] Construct LTR-U6-epegRNA-EF1α-nSpCas9-RT-LTR carrying U6-epgRNA and SpCas9n fusion protein sequence, and construct LTR-U6-nicking sgRNA-EF1α-MLH1dn-LTR carrying U6-sgRNA and EF-1α-MLHdn;
[0101] LTR-U6-epegRNA-EF1α-nSpCas9-RT-LTR was derived from lenti-crispr v2 by replacing SpCas9 with SpCas9n-ert and then inserting a synthetic epegRNA; pLTR-U6-sgRNA-EF-1-MLH1dn-LTR was derived from lenti-crispr v2 by replacing SpCas9 with MLH1dn and then inserting ngRNA via BsmB1; all constructs were confirmed by DNA sequencing;
[0102] Preferably, an integrase-deficient packaging vector carrying the mutation D64V, a vector expressing the lentiviral envelope, and a plasmid of and are transfected into 293T cells to prepare an integrase-deficient lentivirus;
[0103] The ngRNA production method was as follows: annealing the top oligonucleotide 5'CACCG-TCATCCAAGGGCAATTCATC and the bottom oligonucleotide 5'-aaac-20nt-c-3', 20nt is the complementary top oligonucleotide sequence; all clones were confirmed by DNA sequencing, and the primer was derived from the U6 promoter sequence 5'-GGACTATCATATGCTTACCG-3' that drives grRNA expression. Oligonucleotide synthesis and Sanger DNA sequencing were completed by Qingdao Biotechnology Co., Ltd. (Beijing);
[0104] The production, sequencing, validation and application instructions are as follows:
[0105] Production of Lentivirus and Non-integrating Lentivirus:
[0106] Lentiviral vector (LV5 or LV6 indicated, 28 μg), a lentiviral envelope plasmid VSV-G (Catalog #: 8454, Addgene) (7 μg) (Stewart et al., 2003), and a lentiviral packaging plasmid psPAX2 (Catalog #: 12260, Addgene) (21 μg) or an integrase-deficient lentiviral packaging vector (21 μg) (Catalog #: 63586, Addgene) (Courtesy et al., 2011) were mixed together in DMEM phenol (2 ml), then PEI solution (220 μl, 1 μg / μl, Polysciences, 23966-2) was added to the mixture, and the transfection mixture was incubated at room temperature for 15 min and then carefully transferred to a 150 mm cell culture dish with HEK 293T cells at about 70% confluency in the absence of antibiotics. The medium was replaced with fresh medium after 18 h of culture (37 °C, 5% CO2). 24 h after changing the medium, the lentivirus was first collected, and the virus collection was repeated three times at 24 h intervals. The virus-containing medium was mixed and centrifuged at 800g for 5 min; the supernatant was then centrifuged at 25,000g for 90 min at 4°C. Finally, the virus particles were resuspended in 500l of sterile TNE buffer (50mM Tris pH7.8, 130mM NaCl, 1mM EDTA) and then transferred to a microtube and gently rotated at 4C overnight. These dissolved lentiviruses were then titrated (Barde et al., 2010; Salmon and Trono, 2007) and used to infect MVECs in the presence of 8g / ml polybrene or kept at -80°C (Huang et al., 2017b; Lei et al., 2015; Lei et al., 2004; Wu et al., 2021).
[0107] In vitro transduction of endothelial cells:
[0108] When MVECs were grown to 80% confluence in 6-well plates, their culture medium was replaced with fresh medium, and then lentivirus containing LV5 or NILV, or NILV-PE6 containing NILV-LV5 and NILV-LV6 targeting VEGFR2 or -lacZ [10l of each LV, containing 5x109 viral genome particles (vg) / ml] was added to the culture medium, and 8g / ml polybrene was added. At the desired period after infection, cells were collected in 1 extraction buffer (EB, 10mM tri-hcl, pH 7.4, 5mMEDTA, 50mM NaCl, 50mM NaF, 1% Triton X-100, 20g / mL aprotinin, 2mM Na3VO4, 1mM phenylmethylsulfonyl fluoride) for Western blot analysis or in lysis buffer for genomic DNA isolation (Huang et al., 2017b; Lei et al., 2015; Lei et al., 2004; Wu et al., 2021).
[0109] DNA Sequencing:
[0110] MVECs or mouse retinas were collected for genomic DNA extraction according to the rapid DNA extraction procedure of Epicentre (Chicago, IL). Briefly, the cell pellet was resuspended in QuickExtract solution, vortexed, and incubated at 65°C for 6 minutes; the lysate was vortexed again and then incubated at 100°C for 10 minutes. The DNA fragment of the mouse VEGFR2 genomic locus was PCR amplified using high-fidelity Herculase II DNA polymerase. The primers P51 were (forward P51F: 5′-AGCCAGATGAGCGGGTAAAA-3′) and (reverse P51R: 5′-TGAGATTATCAT GAATGAGGCCC-3′). The PCR products were separated in 2% agarose gel, purified with Thermo Scientific gel extraction kit, and used for Sanger DNA sequencing and next-generation sequencing (NGS). Primer synthesis and DNA sequencing were performed by Qingdao Biotechnology Co., Ltd.
[0111] In vivo transduction of endothelial cells:
[0112] NILVs for in vivo application were produced by Shandong Virgin Biotechnology Co., Ltd. (LNC) (Jinan, Shandong). Briefly, lentiviral vectors including pLTR-U6-epegRNA-EF1-nSpCas9(H840A)-eRT-LTR (LV5), pLTR-U6-sgRNA-EF-1MLH1dn-LTR (LV6), and pLTR-EF-1-EGFP-LTR, carrying vectors expressing lentiviral envelope proteins (Addgene) (Stewart et al., 2003) and integrase-deficient lentiviral packaging vectors (Addgene) (Certo et al., 2011), respectively, were transfected into HEK293T cells. NILVs were collected from the culture medium and then concentrated by centrifuge as described above. The concentrated NILVs were titrated, aliquoted, and kept at -80°C until use (Huang et al., 2017b; Lei et al., 2004; Wu et al., 2021).
[0113] NILVs (1 μl, 5 × 109 IU / ml) expressing enhanced green fluorescent protein (EGFP) were injected intravitreally into adult or P12 mice; 5 days later, the eyeballs were isolated and fixed in 3.7% formaldehyde for 2 h. The whole retina was blocked in 5% normal goat serum for 30 min and stained with isolectin B4 (IB4) (1:100 dilution, thermo Scientific), a mouse endothelial cell marker, overnight at 4°C (Huang et al., 2017a). Finally, the whole retina was photographed under a fluorescence microscope after thorough washing (Huang et al., 2017a; Wu et al., 2021).
[0114] Genome Editing of Retinal Cells in a Mouse Model of Oxygen-Induced Retinopathy:
[0115] The experiment was performed as described previously (Connor et al., 2009; Huang et al., 2017a). Briefly, C57BL / 6J litters on postnatal day (P) 7 were exposed to 75% O2 in an oxygen chamber (Biospherix) until P12. NILVs-LV5 and NILVs-LV6 (PE6) targeting VEGFR2 or lacZ were injected intravitreally at P12 (1l, 5.0109 vg / ml). After injection, triple antibiotic (Neo / Poly / Bac) ointment was given and placed in an atmosphere of 21% O2. At P17, mice were euthanized and retinas were carefully removed for western blot analysis, NGS or fixed in 3.7% paraformaldehyde. Mice with a total body weight less than 6 g were eliminated. In the OIR model, each experiment was repeated at least twice, with at least 6 mice in each treatment group. Whole mounts of retina were stained with IB4-Alexa 594 (red) overnight at 4° C. Images were captured under a fluorescence microscope.
[0116] Quantification of Vascular Occlusion and Neovascularization:
[0117] This was performed as described previously (Connor et al., 2009; Huang et al., 2017a; Wu et al., 2021). Briefly, retinal images were imported into Adobe Photoshop CS4 and the polygonal lasso tool was used to trace the vascular area of the entire retina. Once the vascular area was highlighted, the number of pixels was obtained. After selecting the total retinal area, the lasso tool and the “subtract from selection” icon were used to selectively remove the vascularized retina. Only the avascular area was left. After selecting the avascular area, the refresh icon was clicked again to obtain the pixel count of the avascular area.
[0118] When analyzing NVs, the original image is reopened. The Magic Wand tool is selected from the side tool panel on the left side of the screen. On the top tool panel, a tolerance is set that will elevate the level of NV while excluding normal vessels (starting at 50). Click on the NV region with the Magic Wand tool to select it. The NV region has higher fluorescence intensity than the surrounding normal vessels. When the neovascularization vessel is selected, zoom in on the region of interest by holding down the "Alt" key on the keyboard and scrolling up. When all NVs are selected and selected, refresh the icon and record the total number of pixels clicked in the NV region.
[0119] Toxicity examination of PE6-VEGFR2 on mouse eyes:
[0120] Six-week-old C57BL / 6J mice were anesthetized and intravitreally injected with 1 μl (5.0109 vg / ml) of NILV-LV5 and NILV-L6 (PE6) targeting VEGFR2 or lacZ. Four weeks later, electroretinograms (ERGs) were performed as previously described (by light / dark adaptation, using a DIAGNOSYS ColorDome with an internal stimulator) (Dong et al., 2022; Huang et al., 2017a). ERG recordings were performed under dim red light after overnight dark adaptation. Under anesthesia, 0.9% sterile saline was dripped on the cornea of the treated eye to prevent dehydration and electrical contact was made with the recording electrode (gold wire loop), a 25-g platinum needle inserted subcutaneously in the forehead as a reference electrode, and a needle inserted subcutaneously near the tail as a ground electrode. A range of flash intensities were generated using a Diagnosys Espion3 Ganzfeld instrument to test scotopic and photopic responses.
[0121] After euthanasia of the mice, the eyeballs were carefully removed and fixed, and the eyeball sections were stained with hematoxylin-eosin. These images were taken under a light microscope.
[0122] All animal experiments adhered to the American Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research. The investigators performing the analyses were unaware of the treatment groups. All mice were cared for according to ACUC protocols approved by the Institutional Animal Care and Use Committee of Shenzhen University (Shenzhen, China).
[0123] It should be understood that those skilled in the art can make improvements or changes based on the above description, and all these improvements and changes should fall within the scope of protection of the appended claims of the present invention.
Claims
1. A drug for blocking abnormal angiogenesis using enhanced lead editing, characterized in that The agent carries LTR-U6-epegRNA-EF1α-nSpCas9-RT-LTR and LTR-U6-nicking sgRNA-EF1α-MLH1dn-LTR targeting genomic VEGFR2; The sequence of the epegRNA is: The ngRNA (nicking sgRNA) was prepared by annealing the top oligonucleotide 5'CACCG-TCATCCAAGGGCAATTCATC and the bottom oligonucleotide 5'-aaac-20nt-c-3', 20nt being the complementary top oligonucleotide sequence; The nSpCas9 adopts nSpCas9 H840A; The LTR-U6-epegRNA-EF1α-nSpCas9-RT-LTR was used to express the epegRNA of the structured RNA sequence driven by the U6 promoter and the nSpCas9 H840A fusion protein of the codon-optimized reverse transcriptase driven by the EF1α core promoter.
2. A method for preparing a drug for blocking abnormal angiogenesis by enhanced lead editing, which is used to prepare the drug for blocking abnormal angiogenesis by enhanced lead editing as claimed in claim 1, characterized in that: Here’s how to do it: Construct LTR-U6-epegRNA-EF1α-nSpCas9-RT-LTR carrying U6-epegRNA and nSpCas9 fusion protein sequences; LTR-U6-nicking sgRNA-EF1α-MLH1dn-LTR carrying U6-ngRNA and EF1α-MLH1dn was constructed.
3. The method for preparing a drug for blocking abnormal angiogenesis using enhanced lead editing according to claim 2, characterized in that: The integrase-deficient lentivirus carrying LTR-U6-epegRNA-EF1α-nSpCas9-RT-LTR or LTR-U6-nicking sgRNA-EF1α-MLH1dn-LTR was prepared by transfecting an integrase-deficient packaging vector carrying mutation D64V, a vector expressing the lentiviral envelope, and a plasmid containing LTR-U6-epegRNA-EF1α-nSpCas9-RT-LTR or LTR-U6-nicking sgRNA-EF1α-MLH1dn-LTR into 293T cells.
4. The method for preparing a drug for blocking abnormal angiogenesis using enhanced lead editing according to claim 2, characterized in that: The LTR-U6-epegRNA-EF1α-nSpCas9-RT-LTR was made by lent-crispr v2 by replacing nSpCas9 with nSpCas9 H840A and then inserting a synthetic epegRNA derivative.
5. The method for preparing a drug for blocking abnormal angiogenesis using enhanced lead editing according to claim 2, characterized in that: The LTR-U6-nicking sgRNA-EF1α-MLH1dn-LTR was derived by replacing SpCas9 with MLH1dn by lenti-crispr v2 and then inserted into the ngRNA via BsmB1.
6. The method for preparing a drug for blocking abnormal angiogenesis using enhanced lead editing according to claim 2, characterized in that: The pharmaceutical preparation method further comprises the steps of: LTR-U6-epegRNA-EF1α-nSpCas9-RT-LTR or LTR-U6-nicking sgRNA-EF1α-MLH1dn-LTR, lentiviral envelope plasmid VSV-G and lentiviral packaging plasmid psPAX2 or integrase-deficient lentiviral packaging transfection mixture; The transfection mixture was incubated at room temperature, transferred to a cell culture dish, and the lentivirus was collected by centrifuging the virus-containing medium and suspending the virus particles in sterile TNE buffer.
